Retrieve available abstracts of 165 articles: HTML format
Single Articles
June 2025
STAGNO F, Cucci R, Marsili G, Castagnetti F, et al Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response:
Results From the GIMEMA LabNet CML Network Database.
Am J Hematol. 2025 Jun 5. doi: 10.1002/ajh.27733. PubMed
SHAH MV, Arber DA, Hiwase DK TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification,
and Management.
Am J Hematol. 2025;100 Suppl 4. PubMedAbstract available
May 2025
BAZARBACHI A, Galimard JE, Dalle IA, Socie G, et al Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic
Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From
EBMT ALWP.
Am J Hematol. 2025 May 30. doi: 10.1002/ajh.27726. PubMedAbstract available
GANGAT N, Tefferi A CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?
Am J Hematol. 2025 May 29. doi: 10.1002/ajh.27730. PubMedAbstract available
KADIA TM, Jen WY, Bataller A, Bazinet A, et al A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory
Acute Myeloid Leukemia.
Am J Hematol. 2025 May 22. doi: 10.1002/ajh.27723. PubMedAbstract available
KANTARJIAN H, Jabbour E Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and
Monitoring.
Am J Hematol. 2025 May 16. doi: 10.1002/ajh.27708. PubMedAbstract available
OKADA Y, Kondo T, Miyazaki T, Shimazu Y, et al Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic
Transplantation for Chronic Myeloid Leukemia in Chronic Phase.
Am J Hematol. 2025 May 12. doi: 10.1002/ajh.27706. PubMed
CHALANDON Y, Devillier R, Boumendil A, Nguyen S, et al Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute
Lymphoblastic Leukemia Patients: A Registry Study From the Societe Francophone de
Greffe de Moelle et Therapie Cellulaire (SFGM-TC).
Am J Hematol. 2025 May 6. doi: 10.1002/ajh.27701. PubMedAbstract available
April 2025
OLSON LM, Gurney M, Li M, Yao Y, et al Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor.
Am J Hematol. 2025 Apr 28. doi: 10.1002/ajh.27698. PubMed
KAMASO J, Garcia-Serra R, Munne M, Rodriguez-Rivera M, et al Integrating Optical Genome Mapping With TP53 FISH: A Synergistic Approach for
Cytogenomic Analysis in Chronic Lymphocytic Leukemia.
Am J Hematol. 2025 Apr 25. doi: 10.1002/ajh.27690. PubMed
YE Y, Berland ATF, Labopin M, Chen J, et al Better Outcome Following Younger Haploidentical Donor Versus Older Matched
Unrelated Donor Transplant for Fit Patients With Acute Myeloid Leukemia
Transplanted in First Remission: A Study From the Global Committee and the Acute
Leukemia Working Party
Am J Hematol. 2025 Apr 7. doi: 10.1002/ajh.27681. PubMed
TEFFERI A, Arber DA Prognostic Validation of the International Consensus (ICC) Re-Classification of
Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC) Into Genetic
Subcategories.
Am J Hematol. 2025 Apr 2. doi: 10.1002/ajh.27675. PubMed
March 2025
BENITEZ LL, Marx KR, Rausch CR, Buhlinger KM, et al Multicenter Retrospective Evaluation of Treatment for High-Risk Acute
Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium.
Am J Hematol. 2025 Mar 26. doi: 10.1002/ajh.27667. PubMedAbstract available
PETIT C, Higue J, Acheaibi Z, Gilhodes J, et al Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory
or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective
Study.
Am J Hematol. 2025 Mar 15. doi: 10.1002/ajh.27626. PubMed
FATHIMA S, Abdelmagid M, Alsugair A, Begna KH, et al Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid
Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative
Cases.
Am J Hematol. 2025 Mar 13. doi: 10.1002/ajh.27670. PubMedAbstract available
CHIEN KS, Curry JL, Pemmaraju N, Jain N, et al Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia.
Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27654. PubMed
ROJEK AE, McCormick BJ, Cwykiel J, Odetola O, et al Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid
Leukemia: A COMMAND Registry Study.
Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27664. PubMed
ESTEVE J, Nagler A, Labopin M, Versluis J, et al Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid
Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic
Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia
Working Party of
Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27647. PubMedAbstract available
BRUNO JE, Herne CA, Baran AM, VanDerMeid KR, et al Treatment of Relapsed/Refractory CLL Patients With PI3Kdelta Inhibitor and Anti-CD20
Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
Am J Hematol. 2025;100:523-526. PubMedAbstract available
MOORE CG, Stein A, Fathi AT, Pullarkat V, et al Treatment of Relapsed/Refractory AML-Novel Treatment Options Including
Immunotherapy.
Am J Hematol. 2025;100 Suppl 2:23-37. PubMedAbstract available
RAVANDI F Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia.
Am J Hematol. 2025;100 Suppl 2:3-4. PubMed
PRATZ KW, Erba HP Frontline Therapy of AML in the Fit and Younger Population-Incorporating
Molecularly Targeted Agents.
Am J Hematol. 2025;100 Suppl 2:16-22. PubMedAbstract available
GOULART H, Wei AH, Kadia TM Maintenance Therapy in AML: What Is the Future Potential?
Am J Hematol. 2025;100 Suppl 2:38-49. PubMedAbstract available
SHORT NJ, Dillon R Measurable residual disease monitoring in AML: Prospects for therapeutic
decision-making and new drug development.
Am J Hematol. 2025;100 Suppl 2:5-15. PubMedAbstract available
February 2025
QU S, Liu N, Sun Q, Wang H, et al The Molecular Features of Chronic Eosinophilic Leukemia, Not Otherwise Specified.
Am J Hematol. 2025 Feb 25. doi: 10.1002/ajh.27645. PubMed
DE LIMA M, Kebriaei P, Lanza F, Cho C, et al Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem
Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
Am J Hematol. 2025 Feb 24. doi: 10.1002/ajh.27637. PubMed
ROEKER LE, Han Y, Teschemaker A, Mato AR, et al BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.
Am J Hematol. 2025 Feb 17. doi: 10.1002/ajh.27639. PubMed
SU W, Stricherz M, Martin A, Belsey J, et al The Efficacy of Pediatric-Inspired Regimens vs. Hyper-CVAD in the Treatment of
Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic
Review and Meta-Analysis.
Am J Hematol. 2025 Feb 13. doi: 10.1002/ajh.27607. PubMedAbstract available
SHIMONY S, Stahl M, Stone RM Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and
Management.
Am J Hematol. 2025 Feb 12. doi: 10.1002/ajh.27625. PubMedAbstract available
CANALI A, Rieu JB, Lapierre L, Bain BJ, et al BCR::ABL1-Positive Acute Myeloid Leukemia.
Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27633. PubMed
ITONAGA H, Miyazaki Y, Kondo T, Shimazu Y, et al Long-Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for
BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective
Study by Adult CML/MPN and MDS Working Groups of the Japanese Society for
Transplantation
Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27641. PubMed
SENAPATI J, Loghavi S, Marvin-Peek J, Garcia-Manero G, et al Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response
and Outcomes to Contemporary Therapies.
Am J Hematol. 2025 Feb 8. doi: 10.1002/ajh.27628. PubMedAbstract available
Correction to "Secondary-Type Mutations Do Not Impact Prognosis in Acute
Myelogenous Leukemia AML With Mutated NPM1".
Am J Hematol. 2025 Feb 5. doi: 10.1002/ajh.27629. PubMed
SHIMONY S, Garcia JS Sharpening the Tools to Get the Edge on Leukemia.
Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27622. PubMed
CHEN EC, Shimony S, Luskin MR, Stone RM, et al Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.
Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27600. PubMedAbstract available
January 2025
MAYER J, Cicatkova P, Kovacova L, Jarosova M, et al Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at
Diagnosis of Chronic Myeloid Leukemia.
Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27608. PubMedAbstract available
HALLEK M Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis,
Diagnosis, and Therapy.
Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27546. PubMedAbstract available
WEI Q, Hu S, Loghavi S, Toruner GA, et al Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes,
Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid
Leukemia.
Am J Hematol. 2025 Jan 27. doi: 10.1002/ajh.27575. PubMedAbstract available
ENGELMANN R, Flores-Montero J, Schilperoord-Vermeulen J, Ritgen M, et al Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for
Automated Fully Standardized Minimal Residual Disease Detection in Chronic
Lymphocytic Leukemia.
Am J Hematol. 2025 Jan 25. doi: 10.1002/ajh.27604. PubMed
BUTLER JT, Yashar WM, Swords R Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable
Residual Disease Detection in Acute Myelogenous Leukemia.
Am J Hematol. 2025 Jan 7. doi: 10.1002/ajh.27586. PubMedAbstract available
KANTARJIAN H, Short NJ, Jain N, Haddad FG, et al Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young
Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute
Lymphoblastic Leukemia.
Am J Hematol. 2025 Jan 5. doi: 10.1002/ajh.27576. PubMedAbstract available
LUFT T, Gras L, Koster L, Kroger N, et al Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic
Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis
on Behalf of the Chronic Malignancies Working Party of the EBMT.
Am J Hematol. 2025;100:38-51. PubMedAbstract available
RECHER C, Dumas PY, Berard E, Tavitian S, et al Mini-consolidations or intermediate-dose cytarabine for the post-remission
therapy of AML patients over 60. A retrospective study from the DATAML and SAL
registries.
Am J Hematol. 2025;100:23-32. PubMedAbstract available
December 2024
SENAPATI J, Kantarjian HM, Haddad FG, Short NJ, et al Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk
Subtype That Warrants an Independent Prognostic Designation.
Am J Hematol. 2024 Dec 24. doi: 10.1002/ajh.27561. PubMedAbstract available
GHOSH N, Eyre TA, Brown JR, Lamanna N, et al Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase
Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563. PubMed
GANGAT N, Elbeih A, Ghosoun N, McCullough K, et al Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With
Venetoclax + Hypomethylating Agent.
Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564. PubMedAbstract available
CAIROLI R, Gatti A, Grillo G, Stefanucci MR, et al Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding
Factor Leukemia: A Phase II Clinical Trial.
Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27547. PubMedAbstract available
GUERINEAU H, Cayuela JM, Dulucq S, Tran Quang V, et al Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of
Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A
Report From the RESIDIAG Study.
Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27553. PubMed
STUTE N, Koldehoff M Overall Survival in Male Patients With Advanced Hematological Disease (Mostly
Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in
Allogeneic Stem Cell Transplantation.
Am J Hematol. 2024 Dec 3. doi: 10.1002/ajh.27538. PubMed
November 2024
KIRTEK TJ, Chen W, Harris JC, Bagg A, et al Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar
Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A
Study From the Bone Marrow Pathology Group.
Am J Hematol. 2024 Nov 23. doi: 10.1002/ajh.27537. PubMed
ROY MOULIK N, Keerthivasagam S, Chatterjee G, Agiwale J, et al Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A
Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML)
Cohort.
Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27528. PubMedAbstract available
KONUMA T, Kameda K, Morita K, Kondo T, et al Different impacts of granulocyte colony-stimulating factor administration on
allogeneic hematopoietic cell transplant outcomes for adult acute myeloid
leukemia according to graft type.
Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27521. PubMedAbstract available
SCHMALTER AK, Labopin M, Versluis J, Gallego Hernanz MP, et al The role of allogeneic stem cell transplantation in acute myeloid leukemia with
translocation t(8;16)(p11;p13).
Am J Hematol. 2024 Nov 18. doi: 10.1002/ajh.27496. PubMedAbstract available
LIU H, Xu H, Chi P, Feng Z, et al A prophylactic tyrosine kinase inhibitor strategy based on measurable residual
disease pre-transplantation for Ph(+) acute lymphoblastic leukemia undergoing
allogeneic hematopoietic stem cell transplantation: A prospective multicenter
cohort study.
Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27516. PubMedAbstract available
LUO J, Zhang J, Liu L, Wei R, et al Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic
leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.
Am J Hematol. 2024 Nov 4. doi: 10.1002/ajh.27519. PubMed
HEIBLIG M, Gourguechon C, Guilpain P, Bulai-Livideanu C, et al Comparison of prognostic scores according to WHO classification in 170 patients
with advanced mastocytosis and C-finding treated with midostaurin.
Am J Hematol. 2024;99:2127-2139. PubMedAbstract available
DINARDO CD, Pratz KW, Panayiotidis P, Wei X, et al The impact of post-remission granulocyte colony-stimulating factor use in the
phase 3 studies of venetoclax combination treatments in patients with newly
diagnosed acute myeloid leukemia.
Am J Hematol. 2024 Nov 1. doi: 10.1002/ajh.27515. PubMed
October 2024
SHANKER S, Hasserjian RP, Madanat Y, Weinberg OK, et al Impact of myelodysplasia-related mutations on 2022 European LeukemiaNet genetic
risk classification in de novo acute myeloid leukemia with normal karyotype.
Am J Hematol. 2024 Oct 30. doi: 10.1002/ajh.27518. PubMedAbstract available
ONIDA F Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic
leukemia.
Am J Hematol. 2024 Oct 29. doi: 10.1002/ajh.27512. PubMed
Abstracts from the 2024 Lymphoma Leukemia and Myeloma Congress October 16-19,
2024.
Am J Hematol. 2024;99 Suppl 2:S3-S64. PubMed
September 2024
SRINIVASAN N, Olivier T, Haslam A, Prasad V, et al Imatinib remains the best frontline therapy in patients with chronic myeloid
leukemia: Critical analysis of the ASC4FIRST trial.
Am J Hematol. 2024 Sep 28. doi: 10.1002/ajh.27477. PubMed
TEFFERI A, Fathima S, Alsugair AKA, Aperna F, et al PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of
patients with distinct phenotype and superior prognosis.
Am J Hematol. 2024 Sep 27. doi: 10.1002/ajh.27492. PubMedAbstract available
OZGA M, Nicolet D, Mrozek K, Walker CJ, et al White blood cell count levels are associated with inflammatory response and
constitute independent outcome predictors in adult patients with acute myeloid
leukemia aged <60 years.
Am J Hematol. 2024 Sep 16. doi: 10.1002/ajh.27465. PubMed
BADAR T, Narra R, Mims AS, Heckman MG, et al Impact of induction regimens intensity and allogeneic stem cell transplantation
on survival of patients with Philadelphia chromosome-positive acute lymphoblastic
leukemia: A multi-institutional study.
Am J Hematol. 2024 Sep 10. doi: 10.1002/ajh.27475. PubMedAbstract available
BAUER K, Hauswirth A, Gleixner KV, Greiner G, et al BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem
cells in AML and ALL.
Am J Hematol. 2024;99:1721-1731. PubMedAbstract available
August 2024
BARON F, Labopin M, Versluis J, Vydra J, et al Higher survival following transplantation with a mismatched unrelated donor with
posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than
with double unit umbilical cord blood in patients with acute myeloid leukemia in
first co
Am J Hematol. 2024 Aug 31. doi: 10.1002/ajh.27466. PubMedAbstract available
ZIMMERMAN MKA, Wilde L Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the
colon.
Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27467. PubMed
JEN WY, Jabbour E, Short NJ, Issa GC, et al A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia
positive acute lymphoblastic leukemia.
Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27463. PubMedAbstract available
HAZARIKA B, Bain BJ Presentation of chronic myeloid leukemia in basophilic blast crisis.
Am J Hematol. 2024 Aug 23. doi: 10.1002/ajh.27464. PubMed
SHEN Q, Jabbour EJ, Tang G, Fang H, et al Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic
leukemia.
Am J Hematol. 2024 Aug 17. doi: 10.1002/ajh.27462. PubMed
LIPTON JH Imatinib versus newer generation TKIs for upfront therapy in chronic phase
chronic myeloid leukemia: What is the rationale for paying more to get the same
survival benefit?
Am J Hematol. 2024 Aug 14. doi: 10.1002/ajh.27455. PubMed
JABBOUR E, Kantarjian H Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27443. PubMedAbstract available
KANTARJIAN HM, Begna K, Jabbour EJ, Paul S, et al Optimal frontline therapy of chronic myeloid leukemia today, and related musings.
Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27445. PubMed
SMITH CJ, Ruan GJ, Kluck LA, Maberry M, et al BCR-ABL testing in the evaluation of neutrophilia.
Am J Hematol. 2024;99:1651-1654. PubMed
KANTARJIAN HM, Chifotides HT, Haddad FG, Short NJ, et al Ponatinib-review of historical development, current status, and future research.
Am J Hematol. 2024;99:1576-1585. PubMedAbstract available
July 2024
WILLEMSEN M, Smeets P, de Coninck A Isolated peripheral nervous system relapse after allogeneic hematopoietic cell
transplantation for T-cell acute lymphoblastic leukemia.
Am J Hematol. 2024 Jul 30. doi: 10.1002/ajh.27441. PubMed
MOLICA S, Allsup D, Giannarelli D Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic
leukemia.
Am J Hematol. 2024 Jul 23. doi: 10.1002/ajh.27437. PubMed
LOGHAVI S, Wei Q, Ravandi F, Quesada AE, et al Optical genome mapping improves the accuracy of classification, risk
stratification, and personalized treatment strategies for patients with acute
myeloid leukemia.
Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27435. PubMedAbstract available
MARVIN-PEEK J, Gilbert JS, Pollyea DA, DiNardo CD, et al Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where
are we now and where can we go?
Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27434. PubMedAbstract available
BALEV M, Zibara V, Van Hyfte G, Feld J, et al Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk
classification in predicting overall and relapse-free survival in acute myeloid
leukemia.
Am J Hematol. 2024 Jul 5. doi: 10.1002/ajh.27429. PubMedAbstract available
TU S, Zhou L, Huang R, Zhou X, et al Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of
CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.
Am J Hematol. 2024;99:1437-1440. PubMed
PEREZ CARRETERO C, Gonzalez T, Quijada Alamo M, Rigolin GM, et al Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole
cytogenetic abnormality display a high frequency of RPS15 mutations and have a
poor prognosis.
Am J Hematol. 2024 Jul 1. doi: 10.1002/ajh.27421. PubMed
June 2024
LANCE A, Chiad Z, Seegers SL, Paschall SC, et al Hereditary chronic neutrophilic leukemia in a four-generation family without
transformation to acute leukemia.
Am J Hematol. 2024 Jun 27. doi: 10.1002/ajh.27420. PubMedAbstract available
VENANZI A, Cardinali V, Perriello V, Albano F, et al Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid
leukemia.
Am J Hematol. 2024 Jun 22. doi: 10.1002/ajh.27415. PubMed
GARCIAZ S, Dumas PY, Bertoli S, Sallman DA, et al Outcomes of acute myeloid leukemia patients who responded to venetoclax and
azacitidine and stopped treatment.
Am J Hematol. 2024 Jun 20. doi: 10.1002/ajh.27417. PubMedAbstract available
NAGLER A, Ngoya M, Galimard JE, Labopin M, et al Comparable relapse incidence after unrelated allogeneic stem cell transplantation
with post-transplant cyclophosphamide versus conventional anti-graft versus host
disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of
the Ac
Am J Hematol. 2024 Jun 10. doi: 10.1002/ajh.27383. PubMedAbstract available
CLAUDIANI S, Chee L, Fernando F, Brown L, et al Treatment-free remission in CML patients with additional chromosome abnormalities
in the Philadelphia-positive clone or variant Philadelphia translocations.
Am J Hematol. 2024;99:1172-1174. PubMedAbstract available
May 2024
VERONESE L, Bensaber H, Dannus LT, Giannone G, et al Molecular landscape of mature B-cell lymphoproliferative disorders with
BCL3-translocation: A Groupe Francophone de Cytogenetique Hematologique
(GFCH)/French Innovative Leukemia Organization (FILO) study.
Am J Hematol. 2024 May 30. doi: 10.1002/ajh.27384. PubMed
OTHMAN T, Koller P, Tsai NC, Yang D, et al Toxicities associated with tyrosine kinase inhibitor maintenance following
allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive
acute lymphoblastic leukemia.
Am J Hematol. 2024 May 28. doi: 10.1002/ajh.27378. PubMedAbstract available
OTHMAN T, Li S, Zhang J, Pourhassan H, et al Outcomes following allogeneic hematopoietic cell transplantation relapse in
Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol. 2024 May 27. doi: 10.1002/ajh.27365. PubMedAbstract available
DEVILLIER R, Galimard JE, Blaise D, Raiola AM, et al Peripheral blood stem cell versus bone marrow graft for patients >/=60 years
undergoing reduced intensity conditioning haploidentical transplantation for
acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia
Working Party of
Am J Hematol. 2024 May 23. doi: 10.1002/ajh.27343. PubMedAbstract available
KOCKEROLS C, Valk PJM, Dulucq S, Nicolini FE, et al BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid
leukemia patients: An individual participant data meta-analysis.
Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27359. PubMed
LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al Infections in patients with chronic lymphocytic leukemia treated with time
limited targeted drug combinations.
Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367. PubMed
BEWERSDORF JP, Shimony S, Shallis RM, Liu Y, et al Combination therapy with hypomethylating agents and venetoclax versus intensive
induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid
leukemia-A multicenter cohort study.
Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366. PubMed
RANAWEERA ARACHCHIGE T, Mendiburu C, Martin A, Fleury C, et al Clinical and biological characterization of involvement of nasal-associated
lymphoid tissues in chronic lymphocytic leukemia.
Am J Hematol. 2024 May 10. doi: 10.1002/ajh.27357. PubMed
SHOMALI W, Gotlib J World Health Organization and International Consensus Classification of
eosinophilic disorders: 2024 update on diagnosis, risk stratification, and
management.
Am J Hematol. 2024;99:946-968. PubMedAbstract available
CIUREA SO, Kongtim P, Srour S, Chen J, et al Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells
for patients with multiply relapsed and refractory AML.
Am J Hematol. 2024;99:890-899. PubMedAbstract available
ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al Relative prognostic value of flow cytometric measurable residual disease before
allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
Am J Hematol. 2024;99:862-870. PubMedAbstract available
NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete
molecular remission.
Am J Hematol. 2024;99:806-815. PubMedAbstract available
April 2024
YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al Lower relapse incidence with haploidentical versus matched sibling or unrelated
donor hematopoietic cell transplantation for core-binding factor AML patients in
CR2: A study from the Global Committee and the Acute Leukemia Working Party of
the Europea
Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342. PubMedAbstract available
ZHOU Z, Zhuo N, Zhou Y, Sun C, et al Identification of the characteristics and prognostic impact of FUS::ERG and
RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340. PubMed
SZUBER N, Orazi A, Tefferi A Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update
on diagnosis, genetics, risk stratification, and management.
Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321. PubMedAbstract available
SHORT NJ, Jabbour E, Nasr LF, Jain N, et al Characteristics and outcomes of patients with relapsed Philadelphia
chromosome-positive acute lymphoblastic leukemia after failure of a frontline
ponatinib-containing therapy.
Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329. PubMed
CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic
leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304. PubMed
MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al Redefining hyperviscosity in acute leukemia: Potential implications for red cell
transfusions in the microvasculature.
Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308. PubMedAbstract available
KHAN AA, James D, Andresen V, Atkey J, et al Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301. PubMed
LITZOW MR Building a better blinatumomab.
Am J Hematol. 2024;99:512-514. PubMed
HU S, Jabbour EJ, Hu CY, Tang G, et al Recurrent lymphoid and myeloid relapses due to treatment cessations reveal
natural history of Ph-positive B-ALL and pose a diagnostic challenge.
Am J Hematol. 2024;99:721-726. PubMed
March 2024
HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia
chromosome variants do not adversely affect the achievement of treatment-free
remission in chronic myeloid leukemia.
Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307. PubMed
TANG H, Jia W, Jia S, Dong R, et al A new chemotherapy-free regimen of olverembatinib in combination with venetoclax
and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia:
Preliminary outcomes of a prospective study.
Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289. PubMed
PATNAIK MM, Tefferi A Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification
and management.
Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271. PubMedAbstract available
TROUSSARD X, Maitre E, Paillassa J Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and
treatment-Annual updates in hematological malignancies.
Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240. PubMedAbstract available
February 2024
MIRVIS E, Sairam S, Vainieri E, Tona F, et al Pituitary apoplexy in acute promyelocytic leukemia.
Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277. PubMed
JIANG M, Wang X, Yu M, Jiang S, et al Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic
leukemia.
Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272. PubMedAbstract available
SANDBERG Y, Budel LM, Bain BJ Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so
simple.
Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268. PubMed
GANGAT N, Tefferi A Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Am J Hematol. 2024 Feb 20. doi: 10.1002/ajh.27256. PubMedAbstract available
BATALLER A, DiNardo CD, Bazinet A, Daver NG, et al Targetable genetic abnormalities in patients with acute myeloblastic leukemia
across age groups.
Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27236. PubMedAbstract available
KITTAI AS, Hang Y, Bhat SA, Clark A, et al Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma
accounting for small molecule inhibitors: A real-world cohort analysis.
Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241. PubMedAbstract available
PRATZ KW, Jonas BA, Pullarkat V, Thirman MJ, et al Long-term follow-up of VIALE-A: Venetoclax and azacitidine in
chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27246. PubMedAbstract available
AUTORE F, Visentin A, Deodato M, Vitale C, et al Venetoclax infectious risk score to identify patients with chronic lymphocytic
leukemia at high infectious risk during venetoclax treatment: A multicenter
SEIFEM study.
Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247. PubMed
ABAZA Y, Winer ES, Murthy GSG, Shallis RM, et al Clinical outcomes of hypomethylating agents plus Venetoclax as frontline
treatment in patients 75 years and older with acute myeloid leukemia: Real-world
data from eight US academic centers.
Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27231. PubMedAbstract available
CHEN X, Yuan L, Zhang Y, Wang F, et al Advances towards genome-based acute myeloid leukemia classification: A
comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus
Classification.
Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249. PubMedAbstract available
JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227. PubMedAbstract available
HORNAK T, Mayer J, Cicatkova P, Semerad L, et al De novo accelerated phase of chronic myeloid leukemia should be recognized even
in the era of tyrosine kinase inhibitors.
Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229. PubMedAbstract available
BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al Unstable major molecular response as a trigger for next generation
sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232. PubMed
KURITA N, Imahashi N, Chiba S, Tanaka M, et al Comparison of fludarabine-based conditioning regimens in adult cord blood
transplantation for myeloid malignancy: A retrospective, registry-based study.
Am J Hematol. 2024;99:236-244. PubMedAbstract available
GURNARI C, Pascale MR, Vitale A, Diral E, et al Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics
of a nationwide VEXAS cohort.
Am J Hematol. 2024;99:254-262. PubMedAbstract available
DINARDO CD Toward an improved understanding of hypomethylating agent and venetoclax
therapies.
Am J Hematol. 2024;99:152-154. PubMed
BRUNNER AM, Esteve J, Porkka K, Knapper S, et al Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3
antibody, in combination with decitabine or azacitidine in high- or very
high-risk myelodysplastic syndromes.
Am J Hematol. 2024;99:E32-E36. PubMedAbstract available
January 2024
CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al Additional booster doses in patients with chronic lymphocytic leukemia induce
humoral and cellular immune responses to SARS-CoV-2 similar to natural infection
regardless ongoing treatments: A study by ERIC, the European Research Initiative
on CLL.
Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218. PubMedAbstract available
IM A, Quann K, Agha M, Raptis A, et al Phase 2 study of epigenetic priming with decitabine followed by cytarabine for
acute myeloid leukemia in older patients.
Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212. PubMedAbstract available
VARDELL VA, Ermann DA, Fitzgerald L, Shah H, et al T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of
novel treatments.
Am J Hematol. 2024 Jan 19. doi: 10.1002/ajh.27205. PubMedAbstract available
Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute
Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with
CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217. PubMed
BARON F, Efficace F, Cannella L, Stevens-Kroef M, et al Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for
autologous stem cell transplantation in acute myeloid leukemia: Long-term
follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Am J Hematol. 2024 Jan 4. doi: 10.1002/ajh.27196. PubMedAbstract available
MOUKALLED N, Labopin M, Versluis J, Socie G, et al Complex karyotype but not other cytogenetic abnormalities is associated with
worse posttransplant survival of patients with nucleophosmin 1-mutated acute
myeloid leukemia: A study from the European Society for Blood and Marrow
Transplantation Acute Le
Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27187. PubMedAbstract available
PELLAND-MARCOTTE MC, Kulkarni K, Tran TH, Stammers D, et al Risk factors and clinical impact of thrombosis during induction chemotherapy for
pediatric acute lymphoblastic leukemia: A report from CYP-C.
Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27171. PubMedAbstract available
SPONSEILER I, Bandian AM, Pusic P, Lion T, et al Combinatorial treatment options for highly resistant compound mutations in the
kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
Am J Hematol. 2024;99:E9-E11. PubMed
TEFFERI A, Abdelmagid M, Al-Kali A, Patnaik M, et al Granularity in disease classification impacts survival prediction in advanced
systemic mastocytosis: A single institution study of 329 informative cases.
Am J Hematol. 2024;99:21-27. PubMedAbstract available
December 2023
MOLICA S, Shanafelt TD, Allsup D, Giannarelli D, et al Impact of targeted agents on survival of chronic lymphocytic leukemia patients
age >65 relative to age- and sex-matched population.
Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27182. PubMedAbstract available
KARRAR O, Abdelmagid M, Rana M, Iftikhar M, et al Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating
agent in newly diagnosed acute myeloid leukemia: Comparative analysis of
response, toxicity, and survival.
Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27180. PubMedAbstract available
GANGAT N, Karrar O, Iftikhar M, McCullough K, et al Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute
myeloid leukemia: Genotype signatures for response and survival among 301
consecutive patients.
Am J Hematol. 2023 Dec 10. doi: 10.1002/ajh.27138. PubMedAbstract available
JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and
triggers TKI sensitivity switch to quizartinib.
Am J Hematol. 2023;98:E364-E368. PubMed
OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al Immune cell kinetics and antibody response in COVID-19 patients with low-count
monoclonal B-cell lymphocytosis.
Am J Hematol. 2023;98:1909-1922. PubMedAbstract available
November 2023
VALENT P Clinical impact of cytomorphology in mast cell leukemia.
Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27146. PubMed
BATALLER A, Loghavi S, Gerstein Y, Bazinet A, et al Characteristics and clinical outcomes of patients with myeloid malignancies and
DDX41 variants.
Am J Hematol. 2023;98:1780-1790. PubMedAbstract available
October 2023
GHERGUS D, Martin M, Knapp AM, Delmotte F, et al Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between
autoimmunity and lymphoproliferation?
Am J Hematol. 2023 Oct 19. doi: 10.1002/ajh.27137. PubMedAbstract available
SALIBA RM, Kanakry CG, Gadalla S, Kebriaei P, et al Effect of donor age in patients with acute myeloid leukemia undergoing
haploidentical hematopoietic cell transplantation vary by conditioning intensity
and recipient age.
Am J Hematol. 2023 Oct 18. doi: 10.1002/ajh.27126. PubMedAbstract available
KITTAI AS, Skarbnik A, Miranda M, Yong ASM, et al A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in
relapsed or refractory chronic lymphocytic leukemia.
Am J Hematol. 2023 Oct 9. doi: 10.1002/ajh.27110. PubMed
ZHANG L, Yang X, Ge X, Li B, et al CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1
signaling in acute myeloid leukemia.
Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27108. PubMed
SUNG MT, Chen LH, Chiang YW, Jhuang JY, et al Deciphering clonal architecture and evolutionary dynamics of secondary acute
myeloid leukemia and donor-derived myelodysplastic syndrome using single-cell
multi-omics analysis.
Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27121. PubMed
HAZARIKA B, Bain BJ Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia.
Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27114. PubMed
HIRABAYASHI S, Kondo T, Nishiwaki S, Mizuta S, et al Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell
transplantation in patients with Ph(+) ALL: A retrospective nationwide study.
Am J Hematol. 2023;98:1606-1618. PubMedAbstract available
CALABRESI L, Carretta C, Romagnoli S, Rotunno G, et al Clonal dynamics and copy number variants by single-cell analysis in leukemic
evolution of myeloproliferative neoplasms.
Am J Hematol. 2023;98:1520-1531. PubMedAbstract available
Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21,
2023.
Am J Hematol. 2023;98 Suppl 5:S3-S57. PubMed
September 2023
VISENTIN A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, et al The evolving landscape of COVID-19 and post-COVID condition in patients with
chronic lymphocytic leukemia: A study by ERIC, the European research initiative
on CLL.
Am J Hematol. 2023 Sep 29. doi: 10.1002/ajh.27093. PubMedAbstract available
HADDAD FG, Short NJ Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
Am J Hematol. 2023 Sep 27. doi: 10.1002/ajh.27100. PubMed
ZHANG X, Yang J, Li J, Qiu L, et al Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic
leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric
antigen receptor-T cell therapy.
Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094. PubMedAbstract available
TEFFERI A, Pardanani A, Al-Kali A, Alkhateeb H, et al Mast cell cytomorphology and treatment outcome in mast cell leukemia.
Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27105. PubMed
ANIL J, Alnemri A, Lytle A, Lockhart B, et al Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy
in B-acute lymphoblastic leukemia.
Am J Hematol. 2023 Sep 18. doi: 10.1002/ajh.27098. PubMedAbstract available
VON ASMUTH EGJ, Lankester AC, Putter H Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal
time bias?
Am J Hematol. 2023 Sep 15. doi: 10.1002/ajh.27083. PubMed
PATEL PC, Ball S, Jain AG, Wang C, et al Drivers of deep molecular response and long-term outcomes in patients with core
binding factor acute myeloid leukemia.
Am J Hematol. 2023 Sep 13. doi: 10.1002/ajh.27092. PubMedAbstract available
PARDANANI A, Tefferi A, Al-Kali A, Patnaik M, et al Reappraisal of mast cell leukemia based on a single institution review of 16
cases: Mast cell morphology determines clinical outcome.
Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27089. PubMedAbstract available
NATH K, Lee J, Elko TA, Levy L, et al Prospective analysis to determine barriers to allogeneic hematopoietic cell
transplantation in patients with acute leukemia.
Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27084. PubMedAbstract available
FANG H, Medeiros LJ, Wang W Acute myeloid leukemia with mutated TP53: Is this newly proposed entity
oversimplifying a complex group of neoplasms?
Am J Hematol. 2023 Sep 8. doi: 10.1002/ajh.27085. PubMed
RAVANDI F, Cloos J, Buccisano F, Dillon R, et al Measurable residual disease monitoring in patients with acute myeloid leukemia
treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27087. PubMedAbstract available